Slide 1: Fourth Quarter / Full Year Results 2025
Fourth Quarter / Full Year Results 2025 Analyst presentation Investor Relations 26.02.2026
Slide 2: Disclaimer
2 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Disclaimer This presentation contains certain statements that are the Company’s ability to continue to receive adequate neither reported financial results nor other historical products from its vendors on acceptable terms, or a
Slide 3: FY 2025 Group performance
FY 2025 Group performance
Slide 4: Continued progress on purpose-led growth strategy
4 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Continued progress on purpose-led growth strategy “Greater chemistry – between people and planet” 1 2 3 4 Customer Innovative Leading in People focus chemistry sustainability engagement Innovation sales Scope 1 & 2 eNPS cNPS [
Slide 5: Highlights FY 2025 Key messages
5 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Highlights FY 2025 Key messages Flat Sales of CHF 3 915 m – flat local currencies’ sales growth in challenging macroeconomic environment 42 % stable vs. 2024 vs. 32 % in 2024 180 bps EBITDA b.e.i.1 margin improvement driven by
Slide 6: FY 2025 sales: flat LC growth with strong price management across the Group
6 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 FY 2025 sales:1 flat LC growth with strong price management across the Group in slightly deflationary environment 0% -6% 4 152 4 145 0% -1% 1% -1% - 5% 3 915 Care Chemicals flat Care Chemicals - 1 % Lucas Meyer Net impact on Ma
Slide 7: FY EBITDA b.e.i.: increase of margin by 180 bps, driven by performance improvement programs
7 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 FY EBITDA b.e.i.:1 increase of margin by 180 bps, driven by performance improvement programs and cost productivity across entire organization Margin + 180 bps 697 + 20 bps + 30 bps 17.8 % + 70 bps 663 + 60 bps Slightly lower vo
Slide 8: FY 2025 cash conversion: achieving 2027 targets
8 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 FY 2025 cash conversion: achieving 2027 targets, driven by disciplined Capex management and stable operating cash flow + 31 % 273 76 - 75 63 209 Free cash flow1 conversion2 ✓ Disciplined Capex Effective cost Elevated working ma
Slide 9: Performance improvement program set to deliver CHF 80 m by 2027
9 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Performance improvement program (Investor Day 2024) set to deliver CHF 80 m by 2027 Q1: CHF 3 m Run-rate savings of CHF 80 m through BU Program Q2: CHF 9 m and Corporate actions by 2027 with 63 % contribution already achieved i
Slide 10: Q4 2025 Business performance
Q4 2025 Business performance
Slide 11: Q4 sales: Catalysts and Care Chemicals driving volume growth
11 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Q4 sales:1 Catalysts and Care Chemicals driving volume growth – strong pricing management in deflationary environment +1% -7% 1 091 1 103 0% 1% 0% -1% - 6% 1 028 Care Chemicals - 1 %, Care Chemicals + 2 % No impact Net impact
Slide 12: Q4 EBITDA b.e.i.: margin improvement driven by Catalysts and Care Chemicals
12 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Q4 EBITDA b.e.i.:1 240 bps margin improvement driven by Catalysts and Care Chemicals Margin + 240 bps 176 + 0 bps + 10 bps + 120 bps 17.1 % + 110 bps 160 14.7 % Slightly higher Higher volume, Slightly lower volume volume, posi
Slide 13: Fourth Quarter 2025 Care Chemicals
13 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Fourth Quarter 2025 Slight growth with strong margin Care Chemicals improvement Sales1 (in CHF m) +1% -6% – Price: Slightly down due to formula-based pricing in 560 565 industrial segments Base Chemicals and Industrial - 1% 2%
Slide 14: Fourth Quarter 2025 Catalysts
14 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Fourth Quarter 2025 Strong volume increase and Catalysts margin improvement Sales1 (in CHF m) +5% -2% – Refill cycle provided expected strong exit in Q4 271 285 0% 5% 0% - 7% 265 – Price: overall flat with slightly positive pr
Slide 15: Fourth Quarter 2025 Adsorbents & Additives
15 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Fourth Quarter 2025 Softer top-line with stable margin Adsorbents & Additives Sales (in CHF m) -3% -8% – Price: Slightly up with Coatings & Adhesives and 260 0% 253 Adsorbents Americas offsetting slightly lower pricing in the
Slide 16: Group Outlook
LARIANT Greater chemistry -
Slide 17: Outlook 2026: ongoing self-help margin improvement and limited growth
17 Fourth Quarter / Full Year Results 2025 Investor Relations, 26.02.2026 Outlook 2026: ongoing self-help margin improvement and limited growth in a prolonged challenging macroeconomic environment 2025 actual External factors Internal factors 2026 guidance – Macroeconomic challenges, – Portfolio pru
Slide 18: Questions & Answers
CLARIANT™ Questions & Answers Greater chemistry
Slide 19: Thank you
Thank you We place great value on understanding the current views of our investment community. Therefore, we would greatly appreciate your input and feedback via www.clariant.com/Investors/Feedback. Your information will be collected via the secure platform of QuantiFire, who manages this process on